Acceptability and feasibility of S-1 plus cisplatin adjuvant chemotherapy for completely resected non-small cell lung cancer: an open-label, single arm, multicenter, phase 2 trial.

Uematsu, Shugo; Sano, Atsushi; Isobe, Kazutoshi; Usui, Kazuhiro; Matsumoto, Jun; Kiribayashi, Takaharu; Obara, Kiyohaya; Kitami, Akihiko; Murakami, Yoshitaka; Iyoda, Akira

Uematsu, Shugo; Sano, Atsushi; Isobe, Kazutoshi; Usui, Kazuhiro; Matsumoto, Jun; Kiribayashi, Takaharu; Obara, Kiyohaya; Kitami, Akihiko; Murakami, Yoshitaka; Iyoda, Akira.

Afiliação

Uematsu S; Respiratory Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan.
Sano A; Division of Chest Surgery, Department of Surgery, Toho University School of Medicine, Tokyo, Japan.
Isobe K; Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan.
Usui K; Division of Respirology, NTT Medical Center, Tokyo, Japan.
Matsumoto J; Department of General Thoracic Surgery, NTT Medical Center, Tokyo, Japan.
Kiribayashi T; Department of Surgery, Toho University Medical Center Ohashi Hospital, Tokyo, Japan.
Obara K; Division of General Thoracic Surgery, Japan Self-Defense Forces Central Hospital, Tokyo, Japan.
Kitami A; Respiratory Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan.
Murakami Y; Department of Medical Statistics, Toho University School of Medicine, Tokyo, Japan.
Iyoda A; Division of Chest Surgery, Department of Surgery, Toho University School of Medicine, Tokyo, Japan.

J Thorac Dis ; 13(4): 2224-2232, 2021 Apr.

Article em En | MEDLINE | ID: mdl-34012573

Palavras-chave

Lung cancer; adjuvant chemotherapy; feasibility

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Pulmao Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: J Thorac Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google